A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505257-40-00

Acronym

SAGA

Enrollment

Registered

2023-10-18

Start date

2024-04-17

Completion date

2026-01-07

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic esophagogastric adenocarcinoma (Stage IV)

Brief summary

Overall response rate (ORR; complete response [CR] + partial response [PR])

Interventions

DRUGSACITUZUMAB GOVITECAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall response rate (ORR; complete response [CR] + partial response [PR])	—

Countries

Austria, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 6, 2026